AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35033182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg on days 1-5, followed by dexamethasone 10 mg on days 6-10
Number of subjects: 300
Study 35033182 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 6 mg administered once daily intravenously for 10 days
Number of subjects: 300
Study 35033182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg
Number of subjects: 300
Study 35033182 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 6 mg
Number of subjects: 300
Study 35033490 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion reserve (MPR) in patients with HFpEF
Number of subjects: 101
Study 35033490 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular dysfunction (MVD) in patients with HFpEF
Number of subjects: 101
Study 35033490 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite events in HFpEF group during follow-up
Number of subjects: 101
Study 35033490 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR as a predictor of clinical outcome in HFpEF
Number of subjects: 101
Study 35033495 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-GP1 PET-CT
Number of subjects: 75
Study 35033495 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation for 3 months
Number of subjects: 75
Study 35033576 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism-based prenatal cell-free DNA screening
Number of subjects: 20887
Study 35033576 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated cell-free DNA algorithm
Number of subjects: 20887
Study 35033577 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in young patients
Number of subjects: 472
Study 35033577 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality in young patients
Number of subjects: 472
Study 35033577 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial infarction in young patients
Number of subjects: 472
Study 35033577 — intervention group
Group type: EXPERIMENTAL
Intervention: Any revascularization in young patients
Number of subjects: 472
Study 35033999 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 425
Study 35033999 — intervention group
Group type: COMPARATOR
Intervention: Nonbiologic disease-modifying antirheumatic drugs (nbDMARDs)
Number of subjects: 425
Study 35034046 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab 250 mg Q2W or 500 mg Q4W
Number of subjects: 81
Study 35034046 — intervention group
Group type: EXPERIMENTAL
Intervention: Budigalimab
Number of subjects: 81
Study 35034080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension treatment at registration
Number of subjects: 4927
Study 35034080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension treatment at the end of the baseline visit
Number of subjects: 4927
Study 35034080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension control rate
Number of subjects: 4927
Study 35034080 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with hypertension control
Number of subjects: 4927
Study 35034096 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive respiratory support for a median duration of 18 days
Number of subjects: 6268
Study 35034096 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive respiratory support
Number of subjects: 6268
Study 35034116 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) + lower Aβ 42/40 (≤0.103, lowest quartile)
Number of subjects: 470
Study 35034116 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) + higher NfL (>94.55 pg/mL, highest quartile)
Number of subjects: 470
Study 35034116 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) + higher progranulin (>38.4 ng/mL, 3 higher quartiles)
Number of subjects: 470
Study 35034116 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) + lower progranulin (Q1-Q3)
Number of subjects: 470
Study 35034320 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular involvement signs (TIB and VEP)
Number of subjects: 139
Study 35034320 — intervention group
Group type: EXPERIMENTAL
Intervention: High extension of VEP and TIB
Number of subjects: 139
Study 35034655 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraGraft (DG)
Number of subjects: 50
Study 35034655 — intervention group
Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 50
Study 35034655 — intervention group
Group type: COMPARATOR
Intervention: Heparinized Blood (HB)
Number of subjects: 50
Study 35035223 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem treatment
Number of subjects: 58
Study 35035233 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-DEX group (bupivacaine + 1 µg/kg dexmedetomidine)
Number of subjects: 24
Study 35035233 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP-DEX group
Number of subjects: 24
Study 35035233 — intervention group
Group type: COMPARATOR
Intervention: TAP group
Number of subjects: 24
Study 35035955 — intervention group
Group type: EXPERIMENTAL
Intervention: CoV2-PreS-dTM with AS03
Number of subjects: 90
Study 35035955 — intervention group
Group type: EXPERIMENTAL
Intervention: CoV2-PreS-dTM with AF03
Number of subjects: 90
Study 35035955 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 90
Study 35036077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and anti-PD-1 antibody camrelizumab
Number of subjects: 34
Study 35036831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine as an adjunctive therapy
Number of subjects: 0
Study 35036831 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35036831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine as an adjunctive therapy for major depression
Number of subjects: 0
Study 35036831 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 35036998 — intervention group
Group type: EXPERIMENTAL
Intervention: digi-physical eVisits
Number of subjects: 281
Study 35036998 — intervention group
Group type: COMPARATOR
Intervention: office visits
Number of subjects: 281
Study 35037034 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma GDF15 levels
Number of subjects: 1096
Study 35037034 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF15 cutoff values
Number of subjects: 1096
Study 35037052 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity (PA)
Number of subjects: 512
Study 35037052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity (PA)
Number of subjects: 512
Study 35037052 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous BMI
Number of subjects: 512
Study 35037228 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of hyponatremia (Na levels increased by 1, 5, and 10 mmol/L)
Number of subjects: 3880
Study 35037228 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncorrection of hyponatremia on days 4 and 7
Number of subjects: 3880
Study 35037887 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote glucose monitoring using Bluetooth-capable glucose meters and Apple iPod Touch devices.
Number of subjects: 40
Study 35037887 — intervention group
Group type: COMPARATOR
Intervention: Usual care involving keeping written records of glucose values and contacting the diabetes team daily by telephone.
Number of subjects: 40
Study 35037892 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (10-week training program, 3 times per week)
Number of subjects: 78
Study 35037892 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training group (10-week training program, 3 times per week)
Number of subjects: 78
Study 35037892 — intervention group
Group type: COMPARATOR
Intervention: Control group (participation in other physical activities during the same intervention period)
Number of subjects: 78
Study 35037893 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with low total carbohydrate content
Number of subjects: 300
Study 35037893 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet combining low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols and traditional dietary advice
Number of subjects: 300
Study 35037893 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized medical treatment
Number of subjects: 300
Study 35038821 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS methylation high group (≥ 34.82%)
Number of subjects: 294
Study 35038821 — intervention group
Group type: COMPARATOR
Intervention: MOS methylation low group
Number of subjects: 294
Study 35038821 — intervention group
Group type: COMPARATOR
Intervention: OLGA or OLGIM stages
Number of subjects: 294
Study 35038983 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg PRN
Number of subjects: 1044
Study 35039050 — intervention group
Group type: EXPERIMENTAL
Intervention: Beacon Caresystem (personalised mechanical ventilation)
Number of subjects: 0
Study 35039050 — intervention group
Group type: COMPARATOR
Intervention: Standard routine care (control)
Number of subjects: 0
Study 35039057 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced participant information leaflet (PIL/ICF) and a website with animations
Number of subjects: 0
Study 35039057 — intervention group
Group type: COMPARATOR
Intervention: Standard participant information leaflet (PIL/ICF)
Number of subjects: 0
Study 35039091 — intervention group
Group type: EXPERIMENTAL
Intervention: Losmapimod (intervention from the ReDUX4 trial)
Number of subjects: 0
Study 35039142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (Zingiberofficinale) add-on therapy, 399 mg three times per day for 6 weeks
Number of subjects: 21
Study 35039242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal Polyuria Index >0.33 (NPI33)
Number of subjects: 10190
Study 35039242 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal urine production >90 ml/h (NUP90)
Number of subjects: 10190
Study 35039242 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic NP (NPI33)
Number of subjects: 10190
Study 35039242 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic NP (NUP90)
Number of subjects: 10190
Study 35039278 — intervention group
Group type: EXPERIMENTAL
Intervention: Wysa digital mental health intervention
Number of subjects: 61
Study 35039279 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital life coaching (DLC) for 16 weeks starting on day -5 before SCT.
Number of subjects: 15
Study 35039291 — intervention group
Group type: EXPERIMENTAL
Intervention: Camu Camu (CC) supplementation
Number of subjects: 22
Study 35039916 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal tape intervention applied to the anus during days 15-28
Number of subjects: 20
Study 35039916 — intervention group
Group type: COMPARATOR
Intervention: Control period (days 0-14)
Number of subjects: 20
Study 35039952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac 150 mg twice daily
Number of subjects: 50
Study 35039952 — intervention group
Group type: COMPARATOR
Intervention: Observation group (non-randomized control)
Number of subjects: 50
Study 35040037 — intervention group
Group type: EXPERIMENTAL
Intervention: Capaciflector
Number of subjects: 70
Study 35040037 — intervention group
Group type: EXPERIMENTAL
Intervention: Capaciflector during CPET
Number of subjects: 70
Study 35040037 — intervention group
Group type: COMPARATOR
Intervention: Capaciflector at rest
Number of subjects: 70
Study 35040156 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (s.c. doses according to package insert)
Number of subjects: 83
Study 35040160 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ZFP concentration in patients with AN
Number of subjects: 25
Study 35040160 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum LBP and i-FABP levels in patients with AN
Number of subjects: 25
Study 35040160 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI, age, and INR as predictors of serum ZFP in patients with AN
Number of subjects: 25
Study 35040160 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorder symptoms and gastrointestinal complaints in patients with AN
Number of subjects: 25
Study 35040485 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM) with alert transmissions
Number of subjects: 1271
Study 35040485 — intervention group
Group type: COMPARATOR
Intervention: No alert transmissions during RM
Number of subjects: 1271
Study 35040485 — intervention group
Group type: EXPERIMENTAL
Intervention: Last alert-triggered transmission before death
Number of subjects: 1271
Study 35040485 — intervention group
Group type: EXPERIMENTAL
Intervention: Last scheduled transmission before death
Number of subjects: 1271
Study 35040485 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from last alert-triggered transmission to death
Number of subjects: 1271
Study 35040753 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability (abdominal contraction) during exercises (dynamic movement in seated position and march-in-place exercise)
Number of subjects: 55
Study 35040753 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability (abdominal contraction)
Number of subjects: 55
Study 35040753 — intervention group
Group type: COMPARATOR
Intervention: Post-stroke patients
Number of subjects: 55
Study 35040945 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-holding test (BHT)
Number of subjects: 72
Study 35040945 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 minute walk test (6MWT)
Number of subjects: 72
Study 35040961 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher functional connectivity in pre-SMA network
Number of subjects: 120
Study 35040961 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher SMA network segregation
Number of subjects: 120
Study 35040961 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower functional connectivity in pre-SMA network
Number of subjects: 120
Study 35040961 — intervention group
Group type: EXPERIMENTAL
Intervention: No association of transition type with SMA functional connectivity
Number of subjects: 120
Study 35040961 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis
Number of subjects: 120
Study 35041128 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for patients with pneumo-hematoceles of 5 cm or persistent lesions of 3 cm
Number of subjects: 37
Study 35041128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumo-hematocele diameter
Number of subjects: 37
Study 35041128 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruptured pneumo-hematoceles
Number of subjects: 37
Study 35041147 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR+QFR- lesions
Number of subjects: 195
Study 35041147 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-QFR+ lesions
Number of subjects: 195
Study 35041147 — intervention group
Group type: COMPARATOR
Intervention: FFR
Number of subjects: 195
Study 35041449 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA) with subendocardial attenuation analysis
Number of subjects: 735
Study 35041449 — intervention group
Group type: COMPARATOR
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 735
Study 35041482 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon procedures (TAVR or SAVR)
Number of subjects: 5586
Study 35041482 — intervention group
Group type: COMPARATOR
Intervention: Morning procedures (TAVR or SAVR)
Number of subjects: 5586
Study 35041493 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg once daily) plus binimetinib (30 mg twice daily)
Number of subjects: 42
Study 35041672 — intervention group
Group type: EXPERIMENTAL
Intervention: CL Detect Rapid Test on skin slit samples
Number of subjects: 165
Study 35041672 — intervention group
Group type: EXPERIMENTAL
Intervention: CL Detect Rapid Test on dental broach samples
Number of subjects: 165
Study 35041672 — intervention group
Group type: COMPARATOR
Intervention: Microscopy (routine method)
Number of subjects: 165
Study 35041672 — intervention group
Group type: COMPARATOR
Intervention: PCR (reference method)
Number of subjects: 165
Study 35041751 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (duration: 12 months)
Number of subjects: 0
Study 35042068 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab 1500 mg every four weeks
Number of subjects: 867
Study 35042070 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted pyrexia management algorithm
Number of subjects: 0
Study 35042070 — intervention group
Group type: COMPARATOR
Intervention: Historical COMBI-AD control
Number of subjects: 0
Study 35042101 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV care facilitation
Number of subjects: 113
Study 35042101 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 113
Study 35042449 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA with MESS
Number of subjects: 139
Study 35042460 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 200
Study 35042460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy treatment
Number of subjects: 200
Study 35042534 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma SNORD33 signature
Number of subjects: 0
Study 35042555 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCP+ individuals with high antibody levels
Number of subjects: 6780
Study 35042555 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCP+ individuals with hand pain
Number of subjects: 6780
Study 35042555 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CCP+ individuals with foot pain
Number of subjects: 6780
Study 35042555 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level anti-CCP+ individuals without pain in hands or feet
Number of subjects: 6780
Study 35042555 — intervention group
Group type: COMPARATOR
Intervention: Anti-CCP- individuals with one-year follow-up
Number of subjects: 6780
Study 35042555 — intervention group
Group type: COMPARATOR
Intervention: Anti-CCP- individuals with knee pain
Number of subjects: 6780
Study 35042560 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA 500 mg two times daily for 28 days
Number of subjects: 140
Study 35042560 — intervention group
Group type: COMPARATOR
Intervention: Placebo two times daily for 28 days
Number of subjects: 140
Study 35042560 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA 500 mg
Number of subjects: 140
Study 35042560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 35042563 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically guided transversus abdominis plane block (LTAP) with levobupivacaine
Number of subjects: 46
Study 35042563 — intervention group
Group type: COMPARATOR
Intervention: Local wound analgesia with levobupivacaine
Number of subjects: 46
Study 35042564 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome imagery exercise
Number of subjects: 260
Study 35042564 — intervention group
Group type: EXPERIMENTAL
Intervention: Process imagery exercise
Number of subjects: 260
Study 35042564 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined condition (outcome and process imagery)
Number of subjects: 260
Study 35042564 — intervention group
Group type: COMPARATOR
Intervention: Control condition (neither exercise)
Number of subjects: 260
Study 35042564 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 260
Study 35042704 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal screening for HCV and HIV in the emergency room
Number of subjects: 6350
Study 35042704 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out option for testing
Number of subjects: 6350
Study 35042704 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational reasons for not testing
Number of subjects: 6350
Study 35042704 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-HIV coinfection
Number of subjects: 6350
Study 35042709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified health education (I)
Number of subjects: 320
Study 35042709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified health education and SMS/telephonic tracing (I)
Number of subjects: 320
Study 35042709 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified health education, SMS/telephonic tracing and transport reimbursement (I)
Number of subjects: 320
Study 35042709 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation phase (C)
Number of subjects: 320
Study 35043194 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35043241 — intervention group
Group type: EXPERIMENTAL
Intervention: Roadsaver™ dual-layer micromesh stent
Number of subjects: 1967
Study 35043384 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 52
Study 35043682 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent treatment for mCRC patients
Number of subjects: 0
Study 35043682 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using the EuroQol 5-level, 5-dimensional questionnaire
Number of subjects: 0
Study 35043682 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using the Brief Fatigue Inventory
Number of subjects: 0
Study 35043682 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using a modified version of the ACCEPTance by the Patients of their Treatment
Number of subjects: 0
Study 35043686 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab and laser interstitial thermal therapy
Number of subjects: 0
Study 35043689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander cardiopulmonary resuscitation (CPR)
Number of subjects: 104
Study 35043689 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cardiopulmonary resuscitation time
Number of subjects: 104
Study 35043689 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation-associated injury
Number of subjects: 104
Study 35043689 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-critical injuries
Number of subjects: 104
Study 35043689 — intervention group
Group type: EXPERIMENTAL
Intervention: Age comparison of patients with resuscitation injury
Number of subjects: 104
Study 35043976 — intervention group
Group type: EXPERIMENTAL
Intervention: VB124 (MCT4 inhibitor)
Number of subjects: 0
Study 35043976 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MCT4 inhibition and anti-PD-1 immunotherapy
Number of subjects: 0
Study 35043976 — intervention group
Group type: COMPARATOR
Intervention: Higher MCT4 expression in tumor tissues
Number of subjects: 0